while the 36-month beta value is 1.64.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Pacific Biosciences of California Inc. (PACB) is $12.13, which is $3.86 above the current market price. The public float for PACB is 206.29M, and currently, short sellers hold a 11.16% ratio of that floaft. The average trading volume of PACB on March 17, 2023 was 4.21M shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
PACB) stock’s latest price update
Pacific Biosciences of California Inc. (NASDAQ: PACB)’s stock price has decreased by -6.56 compared to its previous closing price of 8.84. However, the company has experienced a -0.48% decline in its stock price over the last five trading sessions.
PACB’s Market Performance
PACB’s stock has fallen by -0.48% in the past week, with a monthly drop of -25.52% and a quarterly drop of -12.41%. The volatility ratio for the week is 8.27% while the volatility levels for the last 30 days are 7.31% for Pacific Biosciences of California Inc. The simple moving average for the last 20 days is -9.93% for PACB stock, with a simple moving average of 8.06% for the last 200 days.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with UBS repeating the rating for PACB by listing it as a “Neutral.” The predicted price for PACB in the upcoming period, according to UBS is $13 based on the research report published on February 02nd of the current year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PACB reach a price target of $12. The rating they have provided for PACB stocks is “Neutral” according to the report published on January 20th, 2023.
Scotiabank gave a rating of “Sector Outperform” to PACB, setting the target price at $12 in the report published on January 05th of the current year.
PACB Trading at -18.31% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.83% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 8.27%, as shares sank -22.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.79% upper at present.
During the last 5 trading sessions, PACB rose by +0.42%, which changed the moving average for the period of 200-days by +48.05% in comparison to the 20-day moving average, which settled at $9.05. In addition, Pacific Biosciences of California Inc. saw 0.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from HENRY CHRISTIAN O, who sold 13,769 shares at the price of $9.49 back on Mar 03. After this action, HENRY CHRISTIAN O now owns 1,222,939 shares of Pacific Biosciences of California Inc., valued at $130,709 using the latest closing price.
Van Oene Mark sale 6,268 shares at $9.49 during a trade that took place back on Mar 03, which means that Van Oene Mark is holding 965,871 shares at $59,502 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -237.58 for the present operating margin
- +38.08 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at -244.92. Equity return is now at value -48.20, with -17.00 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
In a nutshell, Pacific Biosciences of California Inc. (PACB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
